Myeloproliferative disorders

By Murray Jim  

Clinical Medicine, Vol. 5, Iss. 4, 2005-07 ,pp. : 328-332

Royal College Of Physicians

Access to resources Recommend Favorite

Anagrelide is an effective platelet-lowering agent, but its role in the treatment of essential thrombocythaemia has yet to be fully determined

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 11, 2006-11 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Quetiapine: novel uses in the treatment of depressive and anxiety disorders

By Ravindran Arun V   Al-Subaie Abdullah   Abraham Gebrehiwot  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 10, 2010-10 ,pp. : 1187-1204

Informa Healthcare

Access to resources Recommend Favorite

Janus kinase 2 inhibitors in myeloproliferative disorders

By Lucia Eugenio   Recchia Anna Grazia   Gentile Massimo   Bossio Sabrina   Vigna Ernesto   Mazzone Carla   Madeo Antonio   Morabito Lucio   Gigliotti Vincenzo   Stefano Laura De   Caruso Nadia   Servillo Pasquale   Franzese Stefania   Bisconte Maria Grazia   Gentile Carlo   Morabito Fortunato  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 41-59

Informa Healthcare

Access to resources Recommend Favorite

Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia

By Petrides Petro E  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 8, 2004-08 ,pp. : 1781-1798

Informa Healthcare

Access to resources Recommend Favorite